Home Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA
 

Keywords :   


Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

2014-11-25 16:58:52| Biotech - Topix.net

Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy . SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.

Tags: with study children phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11 (CFI-ZCT1J02)
27.11
27.11QUICKSILVER 8/S 130
27.11
27.11Laurene LaVallis Key To Our Love 7 US
27.11THE SCOPE AFTER DARK LP
27.11
27.11DVD
More »